Patent pools and collaborative initiatives: Assessing the efficacy of alternatives to ip in the development of new pharmaceutical drugs, especially for neglected diseases - An empirical analysis

Research output: Contribution to journalArticlepeer-review

Abstract

This article examines the issue of risk in research and development (R&D) pertaining to new pharmaceuticals, especially those aimed at neglected diseases and/or relevant primarily to the developing world. In partic-ular, the article considers the role of patent pools and other forms of non-proprietary models as alternatives to patents (and other types of intellectual property rights) in R&D for new pharmaceuticals. The article concludes that that these mechanisms still achieve very little output and can therefore not currently be considered as viable alternatives to the use of patents in pharmaceutical R&D. Another relevant finding is that many of the existing collaborative initiatives and partnerships for R&D in neglected diseases actually rely on different forms of intellectual property rights.

Original languageEnglish
Pages (from-to)566-571
Number of pages6
JournalEuropean Journal of Risk Regulation
Volume2
Issue number4
DOIs
StatePublished - 2011

ASJC Scopus subject areas

  • Safety Research
  • Law

Fingerprint

Dive into the research topics of 'Patent pools and collaborative initiatives: Assessing the efficacy of alternatives to ip in the development of new pharmaceutical drugs, especially for neglected diseases - An empirical analysis'. Together they form a unique fingerprint.

Cite this